Petrylak, D. P. Et Al. 2017. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. LANCET , vol.390, no.10109 , 2266-2277.

Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., ... Castellano, D.(2017). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. LANCET , vol.390, no.10109, 2266-2277.

Petrylak, Daniel Et Al. "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial," LANCET , vol.390, no.10109, 2266-2277, 2017

Petrylak, Daniel P. Et Al. "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial." LANCET , vol.390, no.10109, pp.2266-2277, 2017

Petrylak, D. P. Et Al. (2017) . "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial." LANCET , vol.390, no.10109, pp.2266-2277.

@article{article, author={Daniel P. Petrylak Et Al. }, title={Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial}, journal={LANCET}, year=2017, pages={2266-2277} }